Sage Therapeutic Stock Price, News & Analysis

Sage Therapeutics recently announced progress in clinical studies, highlighting that SAGE-718 showed improved cognitive function in patients with Alzheimer’s disease. Additionally, they are enrolling patients for the KINETIC 2 study, focusing on SAGE-324 for essential tremor. The company will host its annual FutureCast event today to review its R&D strategy, showcasing advancements in depression and neurology programs. With a focus on GABA and NMDA receptor pathways, Sage aims to address significant brain health disorders.

Sage Therapeutics and Biogen announced promising results from their clinical program for zuranolone, an investigational treatment for major depressive disorder (MDD). In the WATERFALL Study, patients receiving 50 mg zuranolone showed rapid improvements in depressive symptoms as early as Day 3, with effects maintained through Day 42. Safety profiles were consistent with previous studies, showing no increase in adverse events typical of existing antidepressants. Results for older patients (65+) were similarly favorable. These findings were presented at the American College of Neuropsychopharmacology Congress.

Sage Therapeutics and Biogen have announced positive 12-month results for zuranolone 50 mg in the ongoing Phase 3 SHORELINE Study. The study included 199 patients with major depressive disorder (MDD), demonstrating that 74.9% responded to the initial treatment. Zuranolone was well-tolerated, with 68.8% reporting adverse events, mostly mild to moderate. Approximately 80% of responders received just one or two treatment courses over a year, showcasing the drug's potential for quick symptom relief without frequent dosing.

Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced it will host the Sage FutureCast: An R&D and Portfolio Review on December 14, from 8:00 a.m. to 10:00 a.m. ET. The event will outline the company's research and development strategies, focusing on progress in its depression, neurology, and neuropsychiatry programs, including zuranolone, SAGE-324, and SAGE-718. A live webcast will be available on Sage's investor site, with a replay accessible for up to 30 days post-event.

Sage Therapeutics, Inc. (Nasdaq: SAGE) will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1 at 8:30am ET. Investors can access the live webcast via Sage's Investor page. A replay will be made available approximately two hours following the event and archived for up to 30 days. Sage focuses on developing innovative therapies aimed at transforming the lives of individuals with debilitating brain disorders, including programs in depression and neurology.

Sage Therapeutics, a biopharmaceutical company focused on innovative brain therapies, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 15 at 3:20 PM ET. Interested parties can access a live webcast on the company’s investor page at investor.sagerx.com. A replay will be available two hours post-event and archived for 30 days. Sage aims to enhance brain health through its initiatives in depression, neurology, and neuropsychiatry.

Sage Therapeutics reported third-quarter 2021 results, highlighting a successful pre-NDA meeting with the FDA for zuranolone, aimed at treating MDD and PPD. The company plans to submit an NDA in the second half of 2022. Financially, Sage reported a net loss of $130.2 million, an increase from $105.7 million YoY. Revenue from ZULRESSO was $1.4 million, down from $1.6 million. R&D expenses rose to $83.5 million. Cash reserves were approximately $1.8 billion. Sage anticipates continued pipeline progress with three Phase 2 studies expected soon.

Sage Therapeutics, Inc. (NASDAQ: SAGE) will host a live webcast on November 2, 2021 at 8:00 a.m. ET to announce its third quarter 2021 financial results and provide recent business updates. Access to the webcast will be available on the investor page of Sage's website, and a replay will be archived for 30 days. Sage Therapeutics focuses on developing innovative therapies aimed at transforming the treatment of brain disorders.

Sage Therapeutics and Biogen announced plans to submit a New Drug Application (NDA) for the investigational drug zuranolone aimed at treating Major Depressive Disorder (MDD) in the second half of 2022. Following successful discussions with the FDA, their filing will include data from key clinical studies. A subsequent NDA for Postpartum Depression (PPD) is anticipated in early 2023. Both companies aim to launch marketing for zuranolone upon FDA approval, presenting a potential solution for millions suffering from depression worldwide.